Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial

By afschroeder • May 9, 2026

Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol. 2026 May 8:JCO2502027. doi: 10.1200/JCO-25-02027. Epub ahead of print. PMID: 42102329.

Tags: Hematology/Oncology, Publications

Related Posts

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study

McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]